AU2002224437A1 - Monoclonal antibodies to the map protein and method of use in treating or preventing infections - Google Patents

Monoclonal antibodies to the map protein and method of use in treating or preventing infections

Info

Publication number
AU2002224437A1
AU2002224437A1 AU2002224437A AU2443702A AU2002224437A1 AU 2002224437 A1 AU2002224437 A1 AU 2002224437A1 AU 2002224437 A AU2002224437 A AU 2002224437A AU 2443702 A AU2443702 A AU 2443702A AU 2002224437 A1 AU2002224437 A1 AU 2002224437A1
Authority
AU
Australia
Prior art keywords
map protein
bacteria
antibodies
treating
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224437A
Inventor
Paul Domanski
Pratisksha Patel
Joseph M Patti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibitex Inc
Original Assignee
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc filed Critical Inhibitex Inc
Publication of AU2002224437A1 publication Critical patent/AU2002224437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

Monoclonal and polyclonal antibodies to the binding subdomains of the MAP protein, including the Map10 protein, or other immunogenic subregions of the MAP protein, are provided which can be useful in the treatment of and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they serve the double purpose of preventing adherence of the bacteria to host cells and enhancing the killing of the bacteria in an infected host.
AU2002224437A 2000-10-20 2001-10-22 Monoclonal antibodies to the map protein and method of use in treating or preventing infections Abandoned AU2002224437A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24183200P 2000-10-20 2000-10-20
US60241832 2000-10-20
US27728701P 2001-03-21 2001-03-21
US60277287 2001-03-21
PCT/US2001/032550 WO2002034788A1 (en) 2000-10-20 2001-10-22 Monoclonal antibodies to the map protein and method of use in treating or preventing infections

Publications (1)

Publication Number Publication Date
AU2002224437A1 true AU2002224437A1 (en) 2002-05-06

Family

ID=26934627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224437A Abandoned AU2002224437A1 (en) 2000-10-20 2001-10-22 Monoclonal antibodies to the map protein and method of use in treating or preventing infections

Country Status (8)

Country Link
US (1) US20020164337A1 (en)
EP (1) EP1334131B1 (en)
JP (1) JP2004512040A (en)
AT (1) ATE401349T1 (en)
AU (1) AU2002224437A1 (en)
CA (1) CA2425000A1 (en)
DE (1) DE60134881D1 (en)
WO (1) WO2002034788A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434119A1 (en) * 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP0921189B1 (en) * 1997-11-14 2005-01-12 Sankyo Company Limited Transgenic animal allergy models and methods for their use
WO2000012131A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
CA2434119A1 (en) * 2001-01-10 2002-10-03 The Texas A & M University System Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus

Also Published As

Publication number Publication date
DE60134881D1 (en) 2008-08-28
EP1334131A1 (en) 2003-08-13
WO2002034788A1 (en) 2002-05-02
ATE401349T1 (en) 2008-08-15
CA2425000A1 (en) 2002-05-02
US20020164337A1 (en) 2002-11-07
EP1334131A4 (en) 2005-07-20
JP2004512040A (en) 2004-04-22
EP1334131B1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
IL157041A0 (en) Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections
DE69940404D1 (en) Multicomponent vaccines against Staphylococcus aureus
ID21526A (en) 4-HYDROXYQUINOLIN-3-CARBOXOXIDE AND HYDRAZIDE AS ANTI-VIRUS INGREDIENTS
NO20055722D0 (en) Antiseptic preparations, methods and systems
DK0950068T3 (en) Collagen-binding protein compositions and methods of use
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
WO2007053176A3 (en) Method of protecting against staphylococcal infection
ATE335499T1 (en) COMPOSITIONS FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
WO2003037259A3 (en) Methods for the prevention or treatment of bacterial and fungal infections
PT1056454E (en) UTILIZATION OF MACROLID COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
DE69914911D1 (en) PHARMACEUTICAL PREPARATIONS FOR CONTROLLING OR PROPHYLAXIS OF SURFACES INFECTED BY MICRO-ORGANISMS
ATE310088T1 (en) TREATMENT AND DETECTION OF STAPHYLOCOCCAL INFECTIONS
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
AU2002224437A1 (en) Monoclonal antibodies to the map protein and method of use in treating or preventing infections
IL140768A0 (en) Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections
WO2002011549A3 (en) Treatment of mycobacterial infection
WO2004064784A3 (en) Composition and method for preventing or treating a virus infection
ATE446755T1 (en) ANTHELMINTICS FOR PREVENTING PARASITIC INFECTIONS IN HUMAN AND ANIMALS
ATE279195T1 (en) ANTHELMINTICS FOR PREVENTING PARASITIC INFECTIONS IN HUMAN AND ANIMALS III
MX9400210A (en) TREATMENT OF VIRAL INFECTIONS.
RU2001106308A (en) A method for the treatment of purulent infections